WHO Guideline on "Cold" Generation of WFI finalized
Recommendation
17-19 September 2024
GMP Compliance and Technology for the Manufacture of Oral Solid Dosage Forms
In the middle of 2019, the WHO published the draft of the guideline entitled "Production of water for injection by means other than distillation" for the production of WFI by non-distillative methods. This finalised guideline has now been published as Annex 3 in the WHO Technical Report Series (TRS) 1025.
The five-page document (with unchanged seven chapters) has thus gone through two discussion cycles, with most of the comments ultimately aimed at Quality Risk Management, the introduction of warning and action limits and the deletion of the pH test point. However, the document does not provide any precise specifications in this regard, nor does it provide any precise specifications for warning or action limits. Overall, the document remains unspecific and thus close to the draft. A new feature is the specific mention of TOC and conductivity, which are to be monitored by means of online measurements. The pH value has been meaningfully deleted as a test point in monitoring. The requirement for zero risk of contamination of the produced WFI was also deleted and replaced by the demand for controls to minimize this risk. The use of rapid microbiological methods is recommended.
The new document can only be found as Annex 3 in the mentioned WHO TRS 1025, but it is expected that the document will be included in the list of WHO guidelines on the WHO website in the future.
Related GMP News
11.09.2024Humidity in pharmaceutical Cleanroom Walls after a Leakage
28.08.2024FDA Warning Letter to pharmaceutical Manufacturer in Puerto Rico
06.08.2024Is it possible to remove a Biofilm in pharmaceutical Water Systems?
06.08.2024Problems in Clean Room at Contract Manufacturer of sterile Eye Preparations
31.07.2024FDA criticizes Water System at Korean Sunscreen Manufacturer
31.07.2024Containment: What is the Difference between OEB and OEL